drugset

drugset / Trial / NCT01052701

Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment

NCT01052701 ↗

Phase 1 Completed 26 enrolled Johns Hopkins University GlaxoSmithKline · collab University of Colorado, Denver · collab

RandomizedParallel-groupOpen-labelOther

Summary

This research is being done to find out whether abacavir (Ziagen®) lowers the levels of ribavirin (Ribapak®) in the body of persons taking these two drugs.

Timeline

Start: 2009-12
Primary completion: 2012-09
Completion: 2012-12

Publications

Fuchs EJ, Kiser JJ, Hendrix CW, Sulkowski M, Radebaugh C, Bushman L, Ray ML, Andrade A. Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. J Antimicrob Chemother. 2016 Jun;71(6):1597-600. doi: 10.1093/jac/dkw009. Epub 2016 Feb 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Abacavir	Other / unclassified	300 mg	Oral
Comparator	Ribavirin	Small molecule	400 mg	Oral
Comparator	Ribavirin	Small molecule	600 mg	Oral

Indications